Abstract
Purpose
To evaluate whether half‑dose administration of fluorescein and indocyanine green is associated with the incidence of adverse events during fluorescein angiography (FA) and indocyanine green angiography (ICGA).Study design
Retrospective cohort study.Methods
We analyzed 10,435 angiographic examinations in 10,435 unique patients performed using standard doses (fluorescein, 5 mL [500 mg]; indocyanine green, 2 mL [25 mg]) between April 2015 and March 2023, and half doses (fluorescein, 2.5 mL [250 mg]; indocyanine green, 1 mL [12.5 mg]) between April 2023 and March 2024. Explanatory variables included dye dose (half vs. standard), age, sex, diabetes, hypertension, asthma, history of drug allergy, vital signs at examination (systolic/diastolic blood pressure, pulse rate), and meteorological factors (temperature, atmospheric pressure). After univariable analyses, multivariable logistic regression was performed. P Results
Adverse events assessed in the main analyses included rash, nausea/vomiting during FA, ICGA, or combined FA+ICGA, and hypotension. The overall incidence of adverse events was significantly lower in the half‑dose group (6.21%) than in the standard‑dose group (10.65%; P Conclusions
Half‑dose dye administration was associated with lower incidences of rash and nausea/vomiting. Dose reduction may contribute to improved safety in FA and ICGA.